June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Diabetic Retinopathy And the MyVisionTrack® App (DRAMA) Study
Author Affiliations & Notes
  • Yi-Zhong Wang
    Retina Foundation of the Southwest, Dallas, TX
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
  • Yu-Guang He
    Ophthalmology, UT Southwestern Medical Center, Dallas, TX
  • Karl G Csaky
    Retina Foundation of the Southwest, Dallas, TX
    Texas Retina Associates, Dallas, TX
  • Gina Mitzel
    Retina Foundation of the Southwest, Dallas, TX
  • Karen Hernandez
    Retina Foundation of the Southwest, Dallas, TX
  • Song Zhang
    Clinical Sciences, UT Southwestern Medical Center, Dallas, TX
  • Michael B Bartlett
    Vital Art and Science LLC, Richardson, TX
  • Footnotes
    Commercial Relationships Yi-Zhong Wang, Vital Art and Science LLC (C), Vital Art and Science LLC (F), Vital Art and Science LLC (I), Vital Art and Science LLC (P), Vital Art and Science LLC (S); Yu-Guang He, Vital Art and Science LLC (C), Vital Art and Science LLC (I), Vital Art and Science LLC (S); Karl Csaky, None; Gina Mitzel, None; Karen Hernandez, None; Song Zhang, None; Michael Bartlett, Vital Art and Science LLC (E), Vital Art and Science LLC (I), Vital Art and Science LLC (P), Vital Art and Science LLC (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 516. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yi-Zhong Wang, Yu-Guang He, Karl G Csaky, Gina Mitzel, Karen Hernandez, Song Zhang, Michael B Bartlett; Diabetic Retinopathy And the MyVisionTrack® App (DRAMA) Study. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):516.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: It has been shown in a cross-sectional study (Wang, et al. IOVS 54:5497, 2013) that myVisionTrack® (mVTTM), a mobile shape discrimination hyperacuity (SDH) test, is sensitive to the severity of maculopathy. The goal of the DRAMA study (NCT01728883) was to assess the capability of mVTTM to detect visual function improvement associated with anti-VEGF treatments in patients with diabetic macular edema (DME).

Methods: A 12-month prospective longitudinal study was designed to recruit 44 DME patients. To date 33 DME patients (age 62.5±8.0SD yrs) were enrolled in the study. At enrollment, the study eye was under monthly to bi-monthly anti-VEGF injection treatments and had visual acuity (VA) 20/100 or better. Besides the standard care, SDH, VA and SD-OCT central subfield thickness (CST) were obtained at the baseline and every 3 months. The SDH self-test was implemented on an iPad using a spatial 4-alternative forced-choice staircase paradigm (Wang, et al. IOVS 2013 54:ARVO E-Abstract 5019). Clinical judgment of change (CJ-C) was assessed by the treating retinal specialist every 3 months.

Results: For those patients who completed the 3-month visit (n=28), the mean±SD SDH of the study eyes improved from -0.22±0.21 to -0.33±0.21 logMAR (p<0.002). In comparison, mean VA (0.31±0.22 logMAR) and CST (349±114mm) at 3-month showed no significant change from the baseline (0.30±0.21 logMAR and 358±100 mm, respectively). For the patients who completed the 6-month visit (n=23), SDH of the study eyes improved from -0.21±0.20 to -0.33±0.22 logMAR (p<0.001), and CST reduced from 355±89 mm to 316±78 mm (p<0.007), while mean VA (0.29±0.21 logMAR) at 6-month showed no significant improvement from the baseline (0.33±0.21 logMAR). At 3-month, 50% of patients had CJ-C of improvement, with their SDH improved by 0.15±0.17 logMAR (p<0.006). At 6-month, 61% of patients had CJ-C of improvement, with their SDH improved by 0.13±0.18 logMAR (p<0.016) and CST reduced by 44±62 mm (p<0.019). Mean VA related to CJ-C showed no significant change at either 3- or 6-month.

Conclusions: Previous studies (Kaiser, et al. Retina, 33:1863, 2013; Wang, et al. IOVS 2014 55:ARVO E-Abstract 5602) demonstrated that patients with maculopathy had a high compliance of visual function self-testing at home using mVTTM. The interim results of the DRAMA study suggest that mVTTM can be a useful remote monitoring tool at home to track treatment effect and to detect disease condition changes.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×